Anthony A. Rayner

3.7k total citations · 1 hit paper
42 papers, 2.8k citations indexed

About

Anthony A. Rayner is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anthony A. Rayner has authored 42 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Immunology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anthony A. Rayner's work include Immune Cell Function and Interaction (13 papers), CAR-T cell therapy research (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Anthony A. Rayner is often cited by papers focused on Immune Cell Function and Interaction (13 papers), CAR-T cell therapy research (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Anthony A. Rayner collaborates with scholars based in United States, Malaysia and Australia. Anthony A. Rayner's co-authors include Michael T. Lotze, Steven A. Rosenberg, Stephen E. Ettinghausen, Claudia A. Seipp, Yvedt L. Matory, B.J. Lewis, Brett T. Gemlo, Robert Stagg, S O Sharrow and Mary Custer and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Anthony A. Rayner

41 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1985 488 citations Anthony A. Rayner et al. The Journal of Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anthony A. Rayner United States	22	1.3k	1.3k	431	412	370	42	2.8k
Norio Yoshimura Japan	29	620 0.5×	427 0.3×	254 0.6×	1.1k 2.7×	324 0.9×	241	3.2k
Ramesh Saxena United States	27	1.1k 0.8×	297 0.2×	212 0.5×	330 0.8×	375 1.0×	97	3.1k
Irene Schmid Germany	32	808 0.6×	587 0.4×	226 0.5×	480 1.2×	281 0.8×	134	3.0k
Zubin M. Bamboat United States	23	895 0.7×	644 0.5×	210 0.5×	500 1.2×	391 1.1×	38	2.1k
Bernard Charpentier France	40	1.5k 1.1×	648 0.5×	401 0.9×	1.6k 3.8×	415 1.1×	106	5.6k
Thomas Barnetche France	37	1.8k 1.3×	857 0.7×	135 0.3×	376 0.9×	276 0.7×	124	4.6k
Matthew H. Levine United States	30	1.3k 1.0×	456 0.3×	499 1.2×	872 2.1×	263 0.7×	93	3.6k
Michael Lahn United States	35	1.6k 1.2×	1.3k 1.0×	122 0.3×	180 0.4×	520 1.4×	114	3.6k
Diana Davis United Kingdom	14	1.1k 0.8×	293 0.2×	308 0.7×	600 1.5×	85 0.2×	21	3.3k
Josette Eris Australia	29	812 0.6×	613 0.5×	99 0.2×	1.1k 2.8×	213 0.6×	56	3.6k

Countries citing papers authored by Anthony A. Rayner

Since Specialization

Citations

This map shows the geographic impact of Anthony A. Rayner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony A. Rayner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony A. Rayner more than expected).

Fields of papers citing papers by Anthony A. Rayner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony A. Rayner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony A. Rayner. The network helps show where Anthony A. Rayner may publish in the future.

Co-authorship network of co-authors of Anthony A. Rayner

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony A. Rayner. A scholar is included among the top collaborators of Anthony A. Rayner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony A. Rayner. Anthony A. Rayner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rayner, Anthony A., et al.. (2021). The Role of Primary Care Physicians and Reminder Systems in Increasing Colorectal Screening Recommendation [Letter]. Advances in Medical Education and Practice. Volume 12. 107–108. 1 indexed citations

Mace, Michael, Nawal Kinany, Paul Rinne, et al.. (2017). Balancing the playing field: collaborative gaming for physical training. Journal of NeuroEngineering and Rehabilitation. 14(1). 116–116. 47 indexed citations

Hawkins, Michael, Michael B. Atkins, Janice P. Dutcher, et al.. (1994). A Phase II Clinical Trial of Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Colorectal Carcinoma. Journal of Immunotherapy. 15(1). 74–78. 21 indexed citations

Stagg, Robert, Alan P. Venook, Judy L. Chase, et al.. (1991). Alternating Hepatic Intra-Arterial Floxuridine and Fluorouracil: A Less Toxic Regimen for Treatment of Liver Metastases From Colorectal Cancer. JNCI Journal of the National Cancer Institute. 83(6). 423–428. 67 indexed citations

Valone, Frank H., David R. Gandara, Albert Deisseroth, et al.. (1991). Interleukin-2, Cisplatin, and 5-Fluorouracil for Patients with Non-Small Cell Lung and Head/Neck Carcinomas. Journal of Immunotherapy. 10(3). 207–213. 25 indexed citations

Halberg, F., Susan Μ. LaRue, Anthony A. Rayner, et al.. (1991). Intraoperative radiotherapy with localized radioprotection: Diminished duodenal toxicity with intraluminal WR2721. International Journal of Radiation Oncology*Biology*Physics. 21(5). 1241–1246. 18 indexed citations

Parkinson, David, Peter H. Wiernik, Anthony A. Rayner, et al.. (1990). Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.. Journal of Clinical Oncology. 8(10). 1650–1656. 163 indexed citations

Weisfuse, Isaac B., David Parkinson, David R. Snydman, et al.. (1990). An Outbreak of Hepatitis A among Cancer Patients Treated with Interleukin-2 and Lymphokine-Activated Killer Cells. The Journal of Infectious Diseases. 161(4). 647–652. 16 indexed citations

Abrams, Jeffrey S., Anthony A. Rayner, P H Wiernik, et al.. (1990). High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma. JNCI Journal of the National Cancer Institute. 82(14). 1202–1206. 57 indexed citations

10.

Bar, M H, Mario Sznol, Michael B. Atkins, et al.. (1990). Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.. Journal of Clinical Oncology. 8(7). 1138–1147. 66 indexed citations

11.

Farmer, Diana L., et al.. (1990). Cytotoxicity of lymphokine‐activated killer cells against human neuroblastoma cells: Modulation by neuroblast differentiation. Medical and Pediatric Oncology. 18(4). 339–344. 5 indexed citations

12.

Margolin, Kim, Anthony A. Rayner, Michael Hawkins, et al.. (1989). Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.. Journal of Clinical Oncology. 7(4). 486–498. 260 indexed citations

13.

Hohn, David C., Robert Stagg, Michael Friedman, et al.. (1989). A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.. Journal of Clinical Oncology. 7(11). 1646–1654. 349 indexed citations

14.

Boldt, David H., Bonnie Mills, Brett T. Gemlo, et al.. (1988). Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.. PubMed. 48(15). 4409–16. 67 indexed citations

15.

Phillips, Joseph H., et al.. (1987). In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.. Journal of Clinical Oncology. 5(12). 1933–1941. 95 indexed citations

16.

Phillips, Joseph H., Arthur Weiss, Brett T. Gemlo, Anthony A. Rayner, & Lewis L. Lanier. (1987). Evidence that the T cell antigen receptor may not be involved in cytotoxicity mediated by gamma/delta and alpha/beta thymic cell lines.. The Journal of Experimental Medicine. 166(5). 1579–1584. 40 indexed citations

17.

Gemlo, Brett T., Anthony A. Rayner, B.J. Lewis, et al.. (1986). Home support of patients with end-stage malignant bowel obstruction using hydration and venting gastrostomy. The American Journal of Surgery. 152(1). 100–104. 41 indexed citations

18.

Steele, G, et al.. (1982). The effect of adjuvant immunotherapy on tumor recurrence after segmental resection of carcinogen-induced Wistar/Furth primary bowel adenocarcinomas.. The Journal of Immunology. 128(1). 7–10. 15 indexed citations

19.

Couch, Nathan P., Nicholas L. Tilney, Anthony A. Rayner, & Francis D. Moore. (1982). The High Cost of Low-Frequency Events. The Anatomy and Economics of Surgical Mishaps. Survey of Anesthesiology. 26(2). 121–121. 9 indexed citations

20.

Steele, G, et al.. (1981). Effect of major small bowel resection on dimethylhydrazine‐induced bowel carcinogenesis. Journal of Surgical Oncology. 18(1). 87–93. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact